Merck and Pfizer Collaborate with Dako

Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

28-Sep-2015 - As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have announced that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the ...

Agilent to Acquire Dako for $2.2 Billion

23-May-2012 - Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In the ...

Dako and Epitomics enter into strategic alliance on developing and launching IHC diagnostic monoclonal antibodies

23-Mar-2011 - Dako Denmark A/S and Epitomics, Inc. announced that they have entered into a collaboration which will allow the companies to unite competencies to provide the Anatomic Pathology market with state-of-the-art antibodies.Dako's expertise within the field of human cancer diagnostics, including ...

Dako: New diagnostic tests provide hope for patients with stomach cancer

18-Mar-2010 - Dako announced that two of its products have obtained a CE-mark as diagnostic tests for selecting patients with metastatic stomach (gastric) cancer who may benefit from Herceptin(TM) treatment. Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) enable physicians to identify the unique group of ...

Fisher HealthCare becomes exclusive distributor of Flow Cytometry Reagents for Dako Reagent Partnership Division

06-May-2009 - Dako, Reagent Partnership Division, has entered into a five-year agreement with Fisher HealthCare, a division of Thermo Fisher Scientific. Under this agreement, Fisher Healthcare has been granted the exclusive right to distribute Flow Cytometry reagents in the US acute care market, including ...

Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics

30-Jan-2009 - Dako has entered into a collaboration with OSI Pharmaceuticals, Inc. Under the terms of agreement, Dako and OSI Pharmaceuticals, Inc. will collaborate on developing a new cancer diagnostic test as a potential companion product for a cancer therapy. The new cancer diagnostic test is intended to ...

Dako's new Board and Management in place

31-Aug-2007 - Dako's new board is now in place and a new Corporate Vice President, Operations, has been appointed as member of the Corporate Management. Two new board members entered Dako's Board of Directors as of 28 August: - Staffan Ek, former Head of Roches' Diabetes Care business area and former member ...